Health and Me

Ishita Roy

Only In 1 in 10 People With Obesity Have Access To Popular Weight-Loss Drugs, Says WHO

The World Health Organization (WHO) has warned that <span>not enough weight loss jabs</span> will be left for those who need it. While weight loss drugs offer a great potential to tackle the obesity issue that is on the rise, globally. However, the accessibility to those who actually need it is fewer than 1 in 10 people. 

Worldwide, there are one billion obese people, and are the ones calling for widespread and fairer access to these GLP-1 medication. Health prediction says that by 2030, more than two billion people will be obese unless action is taken seriously. 

However, the limited production of the GLP-1 medication, high costs, and supply chain constraints have become a barrier to its universal access. WHO has already added the GLP-1 medication to its 'essential' medicines list for overweight patients with diabetes that countries are advised to provide.

"Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong care. While medication alone won't solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms," says WHO director-general Tedros Adhanom Ghebreyesus.

As per WHO, these drugs represent a new chapter in how society approaches obesity from a lifestyle condition to a complex, preventable, and treatable chronic disease. It says these drugs can be used long-term, for six months or more, but they should be prescribed together with guidance on diet and exercise to help people maintain their weight loss. The problem is only few people can actually access them. "Our greatest concern is equitable access," says Tedros.

Also Read:<a href="https://www.healthandme.com/health-news/eli-lillys-popular-weight-loss-zepbound-price-goes-down-now-more-accessible-article-153232765" data-type="tilCustomLink"> Eli Lilly's Popular Weight Loss Zepbound Price Goes Down, Now More Accessible</a> 

<h2>How Short Are We On Skinny Jabs?</h2>

As of now, WHO notes that under the present scenario of GLP-1 therapies, only 100 million people could benefit them, which is less than 10% of those who need them. 

WHO's latest guidelines are now calling on countries and companies to expand access, through strategies and voluntary licensing. This means companies can grant permission for others to make affordable non-brand versions of its patented drug. 

A patent on semaglutide, the main ingredient in Novo Nordisk’s Wegovy, is set to expire in many countries in 2026. Once that happens, other manufacturers will be able to produce and sell cheaper versions in markets such as India, Canada, China, Brazil and Turkey.

The WHO also says countries need to build healthier environments that support good health and help prevent obesity.

GLP-1 drugs mimic the action of the natural hormone GLP-1 to regulate blood sugar and promote weight loss. They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake. 

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

Health Conditions A-Z

health

not enough obesity jabs

not enough skinny jabs

WHO says we are short on weight loss drugs

not enough weight loss jabs

ozempic shortage

weight loss drugs shortage

health and wellness

Only 1 in 10 People With Obesity Have Access To Popular Weight-Loss Drugs, Says WHO

63.8% Of Delhi-NCR Resident Sought Pollution-related Medical Assistant In 2024, Says Survey

New Warning On Ozempic Use In Australia, After Study Links Popular Weight Loss Drugs With Suicidal Thoughts

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The World Health Organization (WHO) has warned that not enough weight loss jabs will be left for those who need it. While weight loss drugs offer a great potential to tackle the obesity issue that is on the rise, globally. However, the accessibility to those who actually need it is fewer than 1 in 10 people. Worldwide, there are one billion obese people, and are the ones calling for widespread and fairer access to these GLP-1 medication. Health prediction says that by 2030, more than two billion people will be obese unless action is taken seriously. However, the limited production of the GLP-1 medication, high costs, and supply chain constraints have become a barrier to its universal access. WHO has already added the GLP-1 medication to its 'essential' medicines list for overweight patients with diabetes that countries are advised to provide."Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong care. While medication alone won't solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms," says WHO director-general Tedros Adhanom Ghebreyesus.As per WHO, these drugs represent a new chapter in how society approaches obesity from a lifestyle condition to a complex, preventable, and treatable chronic disease. It says these drugs can be used long-term, for six months or more, but they should be prescribed together with guidance on diet and exercise to help people maintain their weight loss. The problem is only few people can actually access them. "Our greatest concern is equitable access," says Tedros.Also Read: Eli Lilly's Popular Weight Loss Zepbound Price Goes Down, Now More Accessible How Short Are We On Skinny Jabs?As of now, WHO notes that under the present scenario of GLP-1 therapies, only 100 million people could benefit them, which is less than 10% of those who need them. WHO's latest guidelines are now calling on countries and companies to expand access, through strategies and voluntary licensing. This means companies can grant permission for others to make affordable non-brand versions of its patented drug. A patent on semaglutide, the main ingredient in Novo Nordisk’s Wegovy, is set to expire in many countries in 2026. Once that happens, other manufacturers will be able to produce and sell cheaper versions in markets such as India, Canada, China, Brazil and Turkey.The WHO also says countries need to build healthier environments that support good health and help prevent obesity.How Do GLP-1 Medications Work?GLP-1 drugs mimic the action of the natural hormone GLP-1 to regulate blood sugar and promote weight loss. They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake. In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

only in 1 in 10 people with obesity have access to popular weight-loss drugs, says who

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Only 1 in 10 People With Obesity Have Access To Popular Weight-Loss Drugs, Says WHO

Before You Take Paracetamol, NHS Advises These Five Groups To Check With A Doctor

Kidney Risks For This Widely Used Blood Pressure Medicine, Says NHS

Scromiting: What Is This Severe Vomiting Syndrome Linked To Long-Term Cannabis Use

Health Conditions A-Z

Only 1 in 10 People With Obesity Have Access To Popular Weight-Loss Drugs, Says WHO

63.8% Of Delhi-NCR Resident Sought Pollution-related Medical Assistant In 2024, Says Survey

New Warning On Ozempic Use In Australia, After Study Links Popular Weight Loss Drugs With Suicidal Thoughts